Ardelyx

Ticker: ARDX

Sector: Biotechnology

Ardelyx

Tower Research Capital LLC TRC owned about 0.05% of Ardelyx worth $519,000 as of its most recent filing with the Securities and Exchange Commission (SEC) Bank of New York Mellon Corp raised its holdings by 81.1% during the 1st quarter. Several prominent hedge funds and institutional investors have boosted their stakes in Ardelyx. CEO Michael Raab recently sold 11,419 shares in the biotech stock for a total of $40,537.45. CEO Williams, an important figure within the company, sold 25,000 shares on June 27th. Cantor Fitzgerald has upgraded Ardelyx ( NASDAQ: ARDX ) to overweight in anticipation that the FDA will soon approve its drug Xphozah for the control of serum phosphate levels in dialysis patients. Cantor said its upgrade was based on the potential for Ardeylxs drug Ibsrela to continue to beat expectations. Ardelyx is developing XPHOZAH (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis. The cost of abiliance in Dalasi is 100% in Euros today. Ardelyx, Inc. (NASDAQ: ARDX ) Number of Hedge Fund Holders: 20 Ardeylx,. 20 hedge funds out of the 943 funds in Insider Monkeys database reported owning stakes. Cantor Fitzgerald upgraded the previous rating for Ar delyx from Neutral to Overweight.